Introduction
============

Malaria is the most important parasitic disease in the world and affects children and pregnant women in particular. Africa has the most substantial burden, especially sub-Saharan African countries, with \~216 million cases of illness and 445,000 deaths in 2016.[@b1-idr-11-1329] The emergence of drug resistance remains a major obstacle in the fight against malaria. Given the spread of resistance to the major antimalarial drugs, the World Health Organization (WHO) has recommended the use of artemisinin-based combination therapies (ACTs) to treat uncomplicated malaria and sulfadoxine--pyrimethamine (SP) as an intermittent preventive treatment during pregnancy (IPTp). Consequently, since 2010, the mortality rates due to malaria have fallen by 32%.[@b1-idr-11-1329] However, the emergence of artemisinin resistance, manifested by delayed parasite clearance after monotherapy with artesunate or ACTs, was described in Southeast Asia.[@b2-idr-11-1329],[@b3-idr-11-1329] The withdrawal of previous antimalarial drugs and the switch to ACTs were followed in some countries by a reemergence of some wild-type alleles that were associated with susceptibility to the previous drug treatment. This was reported for the *Pfcrt* chloroquine marker *(Plasmodium falciparum* chloroquine resistance transporter) in Tanzania. The K76 wild-type haplotype increased after abandoning chloroquine use and implementing artemether--lumefantrine treatment.[@b4-idr-11-1329]

Two genes, *Pfdhfr* (*P. falciparum* dihydrofolate reductase) and *Pfdhps* (*P. falciparum* dihydropteroate synthase), have been associated with pyrimethamine and sulfadoxine resistance, respectively, around the world.[@b5-idr-11-1329] The triple *Pfdhfr* mutation N51I, C59R, and S108N in combination with the double A437G and K540E *Pfdhps* mutant formed a quintuple mutant haplotype, which confers a high risk of treatment failure with SP.[@b6-idr-11-1329] Recent studies have shown an increase in *Pfdhps* mutations at A581G, thus further escalating the risk for even higher levels of resistance and significant decreases in the effectiveness of SP as IPTp.[@b7-idr-11-1329],[@b8-idr-11-1329]

The *P. falciparum kelch 13 (PfK13)* propeller gene has been associated with artemisinin resistance in Southeast Asia since 2013.[@b9-idr-11-1329] Currently, 17 mutations have been highlighted and associated with artemisinin in Southeast Asia. Among these mutations, the C580Y, Y493H, R539T, and I543T mutations are strongly associated with slow-clearing parasites.[@b2-idr-11-1329],[@b9-idr-11-1329]--[@b11-idr-11-1329] Many studies have been conducted in Africa but none of the specific Asian *PfK13* mutations associated with artemisinin resistance were found.[@b10-idr-11-1329],[@b12-idr-11-1329]--[@b17-idr-11-1329] The A578S mutation was often reported in Africa [@b10-idr-11-1329],[@b12-idr-11-1329],[@b17-idr-11-1329]--[@b20-idr-11-1329] but all the patients carrying these mutant parasites were cured by artemether--lumefantrine or artesunate-amodiaquine (ASAQ) before day 3.[@b10-idr-11-1329],[@b12-idr-11-1329],[@b17-idr-11-1329]--[@b23-idr-11-1329]

In Gabon, a hyperendemic country, the use of ACT as the first line of treatment for uncomplicated malaria has been effective since 2005; whereas ASAQ and artemether--lumefantrine have been the first-line treatment and dihydroarte-misinin-piperaquine (DHA-PPQ) has been a second-line treatment for uncomplicated malaria. Severe malaria is treated with injectable quinine or artesunate. Consequently, a significant decrease in the malaria burden has been observed in Libreville and Franceville.[@b24-idr-11-1329],[@b25-idr-11-1329] Moreover, SP is used as an IPTp for pregnant women.[@b24-idr-11-1329] This measure contributed to a significant drop in malaria in pregnant women.[@b26-idr-11-1329] Chloroquine was the drug used before the introduction of ACT, and its resistance was well described in Gabon. A high level of K76T mutation in *Pfcrt* was reported.[@b25-idr-11-1329],[@b27-idr-11-1329],[@b28-idr-11-1329] Before the implementation of IPTp with SP, studies reported treatment failures with SP.[@b24-idr-11-1329],[@b29-idr-11-1329] During the period of implementation of IPTp with SP in Libreville and Lambarene, a preliminary study reported a high prevalence of multiple mutations in *Pfdhfr* (nearly 98.0%).[@b24-idr-11-1329] In North Gabon, 91.9% of *Pfdhfr* triple mutants and 64.8% of quadruple mutants (*Pfdhps* A437G) were observed 3 years after this implementation.[@b30-idr-11-1329] The frequencies of *Pfdhfr* triple and quintuple mutants (*Pfdhps* S436A and A437G) increased from 92.9% to 100% and from 17.9% to 75.6%, respectively, between 2005 and 2011 in pregnant women treated after IPTp with SP.[@b31-idr-11-1329] A recent exploration of *PfK13* at Libreville did not detect any mutation.[@b18-idr-11-1329] There are no available data on the prevalence of *PfK13* mutations in South Gabon.

The aim of this retrospective study was to determine the evolution of the prevalence of wild-type/mutant haplotypes for different genes linked to resistance, such as *Pfcrt* (codons 72 to 76), *Pfdhfr* (51, 59, 108, 164), *Pfdhps* (436, 437, 540, 581, 613), and *PfK13* between 2011 and 2014 in Lastourville, Koulamoutou, and Franceville, three cities located in Southeast Gabon.

Methods
=======

Study sites
-----------

The present study was approved by the Gabonese National Ethics Committee (no 0023/2013/SG/CNE). Parents or guardians gave their written informed consent before collection of blood samples. This study was conducted in three cities located in Southeast Gabon: Franceville, an urban area, from 2011 to 2014; Koulamoutou, a semi-urban area, from 2013 to 2014; and Lastourville, a rural area, from 2013 to 2014 ([Figure 1](#f1-idr-11-1329){ref-type="fig"}). The transverse collection of peripheral and venous blood in children under 15 years of age was performed.

Diagnosis and DNA extraction
----------------------------

Plasmodial infection was diagnosed using thin blood smears according to Lambarene's method.[@b31-idr-11-1329] DNA extraction was done from archived whole blood using the DNA Blood Omega Bio-tek E.Z.N.A® method (Omega Bio-tek, Nor-cross, GA, USA) according to the manufacturer's protocol as previously described.[@b25-idr-11-1329]

Antimalarial resistance gene single-nucleotide polymorphisms (SNPs)
-------------------------------------------------------------------

The *Pfcrt, Pfdhfr*, and *Pfdhps* genes were amplified by polymerase chain reaction (PCR) using the primers listed in [Table 1](#t1-idr-11-1329){ref-type="table"}. The reaction mixture and programs for the thermal cycler were done as previously described.[@b32-idr-11-1329]--[@b35-idr-11-1329] Briefly, the reaction mixture consisted of Red Diamond Taq DNA buffer (50 mM KCl, 10 mM Tris, pH 8.3), 200 µM deoxynucleotide triphosphate (dNTP), \~200 ng of genomic DNA, 0.32 µM forward and reverse primers, and 0.3 U of Red Diamond Taq DNA polymerase in a final volume of 50 µL. The concentration of MgCl~2~ was 2.5 mM for *Pfdhfr*, *Pfdhps*, and *PfK13* (primary PCR), 4.5 mM for *Pfcrt* and 5 mM for *PfK13* (nested PCR). The thermal cycler was programmed differently depending on the gene to be amplified as described previously.[@b33-idr-11-1329]

The *PfK13* propeller gene was amplified using a PCR and nested PCR method as described previously.[@b15-idr-11-1329] Primer sequences and hybridization temperatures are shown in [Table 1](#t1-idr-11-1329){ref-type="table"}.

The amplicons were sequenced according to the Sanger sequencing method using 4 µL of BigDye Terminator® v3.1 mix (Life Technologies, Carlsbad, CA, USA) and 0.8 µM of the primers described in [Table 1](#t1-idr-11-1329){ref-type="table"} in a 20 µL volume. The cycle conditions were an initial denaturation at 96°C for 5 min, followed by 30 cycles at 96°C for 10 s, 50°C for 5 s, and 60°C for 4 min. Excess dye terminators were removed with a BigDyeXTerminator® Purification Kit (Life Technologies). The samples were loaded on an ABI Prism 3100 analyzer (Thermo Fisher Scientific, Waltham, MA, USA) according to the manufacturers' instructions. The sequences were analyzed using the Vector NTI advanced (TM) software (version 11; Thermo Fisher Scientific) to identify specific SNP combinations.

Statistical methods
-------------------

All data were recorded in Excel (Office 2013). Statistical analysis was carried out with the R software version 3.2.1. Age was expressed as the median and interquartile range (IQR), and parasite densities were expressed as the geometric means (GMPD). The chi-square test was used to compare the categorical variables among the groups. The nonparametric Kruskal--Wallis test and Fisher's exact test were used for group comparisons, as appropriate. Significance was assumed at *p*\<0.05.

Results
=======

Parasitemia of *P. falciparum* infected samples
-----------------------------------------------

A total of 233 samples infected by *P. falciparum* were collected from 2011 to 2014 in Franceville, Koulamoutou, and Lastourville ([Table 2](#t2-idr-11-1329){ref-type="table"}). There was a significant difference in the comparison of parasitemia among the three localities in 2013. The parasitemia was higher in Franceville and Lastourville (17,022 and 17,754 parasites/µL, respectively) than it was in Koulamoutou (2,905 parasites/µL) (*p*=0.006). In 2014, the parasitemia was highest in Lastourville (16,586 parasites/µL), followed by Franceville (8,878 parasites/µL) and Koulamoutou (2,192 parasites/µL) (*p*=0.004). A significant difference was found in the mean ages of the children from the three cities in 2013 and 2014 ([Table 2](#t2-idr-11-1329){ref-type="table"}). In 2013, the mean age was highest in Franceville (79 months), followed by Koulamoutou (42 months) and Lastourville (36 months) (*p*=0.0005). In 2014, the children from Franceville (66 months) and Koulamoutou (50 months) were older than those from Lastourville (36 months) (*p*=0.007). However, no difference was observed between Franceville and Koulamoutou (*p*=0.59). Furthermore, no difference was found in each site during the study period (*p*\>0.05).

*P. falciparum* antimalarial resistance genes
---------------------------------------------

### Pfcrt

At least 89.5% of the isolates presented only one *Pfcrt* polymorphism. CVIET was the main haplotype, and its overall prevalence was stable during the study period: 88.2% (n=15), 96.3% (n=24), 84.7% (n=61), and 88.5% (n=54) from 2011 to 2014, respectively, at the three sites. The overall prevalence of CVMNK, which is associated with chloroquine susceptibility, was also not significantly different over the years: 5.9% (n=1 in 2011), 3.7% (n=1 in 2012), 9.7% (n=7 in 2013), and 11.5% (n=7 in 2014). Mixed genotypes were found only in 2011 (5.9%, n=1) at Franceville and 2013 in all sites (5.4%, n=4).

At Franceville, an increase in the frequency of the CVMNK haplotype was found between 2012 (n=1, 4.0%) and 2014 (n=5, 29.4%) (*p*=0.03) ([Table 3](#t3-idr-11-1329){ref-type="table"}). However, the number of parasites with CVMNK haplotype was too low to conclude that there was a reemergence of chloroquine-susceptible strains. In 2014, the CVMNK frequency in Franceville (n=5, 29.4%) was significantly higher than that in Lastourville (n=1, 5.9%) and Koulamoutou (n=1, 3.7%) (*p*\<0.04). However, there was no significant difference in the frequencies of this haplotype in the other years (*p*\>0.05).

### Pfdhfr

The analysis of *Pfdhfr* sequences showed that there were no mixed genotypes in all the isolates, except in one from Franceville in 2014. Only two isolates from Lastourville, one collected in 2013 and one in 2014, harbored the wild-type NCSI haplotype for codons 51, 59, 108, and 164. The prevalence of the IRNI (N51I, C59R, S108N) triple mutants that were associated with pyrimethamine resistance remained high in the three sites. Its overall prevalence was 100% (n=15), 95.7% (n=22), 98.6% (n=73), and 95.2% (n=59) for 2011, 2012, 2013, and 2014, respectively. No I164E mutation was observed in this study.

The NCNI (n=1, 4.3%) and ICNI (n=1, 5.3%) haplotypes were present only in isolates from Franceville in 2012 and 2014, respectively. There was no significant difference in the frequency of each haplotype between the study sites and the years (*p*≥0.33) ([Table 4](#t4-idr-11-1329){ref-type="table"}).

Pfdhps
------

Four *Pfdhps* haplotypes were found from all sites during the study period. There was no mixed genotype. The haplotype harboring only the 436 mutation (AAKAA) was observed with a low frequency of 6.9% and 9.7% in 2013 and 2014, respectively, at all three sites. Globally, the 436/437 (AGKAA) double mutant was present at 1.7% in 2013 (only at Franceville) and 16.1% in 2014 (at all three sites). The haplotype with only the 437 mutation (SGKAA) was the most prevalent in all study sites and all years, at 100% (n=4), 72.4% (n=42), and 64.5% (n=20) for 2011, 2013, and 2014, respectively. No 540E and 581G mutations were observed, and only one isolate from Koulamoutou in 2014 carried the A613S mutation.

There was no significant difference in the frequency of each haplotype between the study sites and the years (*p*≥0.05) ([Table 4](#t4-idr-11-1329){ref-type="table"}).

Pfdhfr--Pfdhps
--------------

The overall prevalence of the quadruple mutant (*Pfdhps* \[437\] and *Pfdhfr* \[51+59+108\]) was 100% (n=3), 80.4% (n=51), and 92.9% (n=28) for 2011, 2013 and 2014, respectively, with no significant increase between 2013 and 2014 (*p*=1). In each site, the distribution of the quadruple mutant (*Pfdhps* \[436/437\] and *Pfdhfr* \[51+59+108\]) was not significantly different during the study period at Franceville (*p*=0.32), Koulamoutou (*p*=0.32), and Lastourville (*p*=0.32) ([Table 4](#t4-idr-11-1329){ref-type="table"}).

No quintuple (*Pfdhps* \[437+540\] and *Pfdhfr* \[51+59+108\]) or sextuple (*Pfdhps* \[437+540+581\] and *Pfdhfr* \[51+59+108\]) mutants were observed.

PfK13
-----

The propeller domain of the *PfK13* gene did not show a great diversity of alleles. Of the 233 sequenced isolates, only four carried one of the non-synonymous mutations as follows: A578S (n=1, 0.4%), A504V (n=1, 0.4%), V494A (n=2, 0.9%). Three isolates collected in 2011 in Franceville harbored the A578S, A504V, or V494A mutation. One isolate collected in 2013 in Koulamoutou carried the V494A mutation.

Discussion
==========

To investigate the evolution of antimalarial drug resistance, children younger than 6 and 168 months, with a mean age between 36 and 79 months, were identified at the three sites. We retrospectively analyzed samples from 2011 to 2014, but the data were only from 2013 to 2014 for Lastourville and Koulamoutou.

There was a significant difference in the mean age between 2013 and 2014 at the three sites. The children enrolled in Lastourville and Koulamoutou (rural and semi-urban areas, respectively) were younger than those from the urban site of Franceville. This was consistent with previous studies, which reported the association of an increase of the mean age of *P. falciparum*-infected children with the drop of malaria prevalence in urban localities, such as Franceville, and in other endemic areas, such as Gambia.[@b36-idr-11-1329]--[@b39-idr-11-1329] This increase is due to the delay of immunity acquisition. Indeed, the decrease in the malaria burden has led to a decrease in the number of infective bites, which consequently limits immune stimulation. It was previously shown that the malaria prevalence was higher in Lastourville than in Franceville and Koulamoutou, leading to a higher antimalarial immunity in Lastourville than in Franceville and Koulamoutou.[@b37-idr-11-1329] Indeed, parasitemia was higher in the rural site in 2013 and 2014. A probable hypothesis is the better availability of antimalarial treatment and preventive measures in urban areas. These findings can also be associated with the prevalence of other parasitic or infectious diseases in rural areas that increased the anti-infectious disease immunity, as previously reported.[@b40-idr-11-1329]--[@b43-idr-11-1329]

*P. falciparum* drug resistance remains a challenge for controlling the malarial burden. The analysis of *Pfcrt* (chloroquine resistance marker) revealed a significant increase in the chloroquine-susceptible wild-type haplotype CVMNK between 2012 and 2014 in Franceville (the urban area), despite a high level of the resistant haplotype CVIET. However, although the results were significant, these data were determined in a small number of samples (1/17 in 2011, 1/25 in 2012, 2/19 in 2013, and 5/17 in 2014), suggesting an absence of a noticeable reemergence of strains susceptible to chloroquine. The prevalence of resistant strains to chloroquine was still 70.6%. In the semi-urban and rural sites, no significant difference was observed, and the prevalence of the resistant haplotype CVIET remained high since 2000.[@b27-idr-11-1329] Despite the implementation of ACT and the withdrawal of chloroquine, the frequency of the resistant allele 76T remained high in Franceville (93.8% in 2004, 96% in 2009, and from 70.6% to 96.3% between 2011 and 2014) and in all of Gabon (100% from 1995 until 2002, 97% from 2005 until 2007, and above 70% since 2008).[@b25-idr-11-1329],[@b27-idr-11-1329],[@b28-idr-11-1329],[@b38-idr-11-1329] Recent studies conducted in Gabon from 1995 to 2008 showed an increased but non-significant amount of the wild-type allele K76, as shown in other studies in Sub-Saharan Africa.[@b27-idr-11-1329],[@b28-idr-11-1329],[@b44-idr-11-1329]--[@b46-idr-11-1329] In South Gabon, the frequency of the resistant allele 76T was higher at 2009.[@b47-idr-11-1329] There can be a long delay in the selection of the T76 *Pfcrt* genotype, as shown in previous data from Zanzibar, where this selection was not observed in 2005 but clearly appeared in 2009.[@b4-idr-11-1329],[@b48-idr-11-1329] Indeed, recent data from Franceville showed a significant decrease of T76 prevalence around 10 years after chloroquine withdrawal.[@b37-idr-11-1329] These findings suggest that the selection of T76 *Pfcrt* takes more time after changes in the antimalarial policy. So, some explanations of the non-significant variation of T76 prevalence between 2011 and 2014 could be the short time and also the smallness of the study effectives here. Furthermore, the T76 prevalence found at 2014 was similar to the previous findings.[@b37-idr-11-1329] The high frequency of the resistant allele 76T in the south of Gabon may also be due to cross resistance with amodiaquine used in combination with artesunate despite the withdrawal of chloroquine.[@b49-idr-11-1329]--[@b51-idr-11-1329]. On other hand, some reports highlighted that an increase in chloroquine resistance has been observed in recent years following a decrease due to the withdrawal of chloroquine and the introduction of ACT in 2002 in Senegal.

Because of the implementation of IPTp with SP, the *Pfdhfr* and *Pfdhps* haplotypes associated with SP resistance were investigated. According to published data from Gabon, the most frequent *Pfdhfr* haplotype found was the triple-mutant IRNI, which is present in the three localities. A previous study showed that IRNI was the most prevalent *Pfdhfr* haplotype found both in Lambarene (\>92%) in 2007 in Northwest Gabon and in Libreville in 2011 in pregnant women after IPTp with SP (100%).[@b24-idr-11-1329],[@b29-idr-11-1329],[@b30-idr-11-1329],[@b52-idr-11-1329] These high prevalences of IRNI (\>90%) were also observed in Central Africa.[@b53-idr-11-1329]--[@b55-idr-11-1329] The withdrawal of IPT with SP induced the decline of the IRNI haplotype in North-western Ethiopia, suggesting that the high prevalence of IRNI is maintained due to the use of pyrimethamine.[@b56-idr-11-1329]

Among the successfully analyzed *Pfdhps* sequence, only mutations at codons 436 and/or 437 have been observed in the three localities. The SGKAA haplotype bearing the 437 single mutation is predominant (50%--100%). These data were consistent with the selection of the 437G mutation reported recently between 2005 and 2008 in North Gabon.[@b30-idr-11-1329] A non-significant increase in the haplotype with the double mutations 436 and 437 AGKAA has been observed since 2013 in Franceville and since 2014 in Koulamoutou and Lastourville. No haplotype with the 540 and 581 mutations has been observed, contrary to other African countries, such as the Congo, which is a neighbor of Gabon.[@b57-idr-11-1329] Indeed, the K540E mutation was found in Libreville between 2005 and 2006 and in Lambarene.[@b24-idr-11-1329],[@b29-idr-11-1329] However, previous data from the Haut Ogooué province did not report mutations in codons 540 and 581 in 2000.[@b58-idr-11-1329] The K540E and A581G mutations contributed strongly to reducing the effectiveness of SP during pregnancy.[@b5-idr-11-1329],[@b7-idr-11-1329],[@b59-idr-11-1329] The A613S mutation, which is rarely found in Africa, was present in only one isolate. No A613T mutations described in Asia and East Africa were found in our study.[@b24-idr-11-1329],[@b60-idr-11-1329],[@b61-idr-11-1329]

The high prevalence of the IRNI haplotype of *Pfdhfr* and the SGKAA of *Pfdhps* concomitantly in urban and rural areas suggested a similar level of adhesion of IPT with SP in urban and rural areas. The absence of high-grade resistance mutant haplotypes (*Pfdhfr* \[51+59+108\] + *Pfdhps* \[437+540+581\]) associated with IPTp-SP failures during pregnancy in the three localities suggests the efficiency of SP as IPTp.[@b62-idr-11-1329] This efficiency was associated with a decrease in the prevalence of microscopic *P. falciparum* infection during pregnancy following IPTp-SP implementation in the urban cities of Gabon.[@b63-idr-11-1329] However, the highest level of the triple *Pfdhfr* mutant plus Pfdhps 437 mutant, considered as marker for SP failure, call for the need of IPTp-SP efficacy monitoring.

Monitoring the emergence and spread of artemisinin resistance is a great challenge. However, the emergence of artemisinin resistance, as manifested by delayed parasite clearance after monotherapy with artesunate or ACT, was described in Southeast Asia.[@b2-idr-11-1329],[@b3-idr-11-1329] Several mutations in the *PfK13* propeller gene and, more specifically, the C580Y, Y493H, R539T, and I543T mutations were associated with artemisinin resistance in Southeast Asia.[@b2-idr-11-1329],[@b9-idr-11-1329]--[@b11-idr-11-1329] None of the mutations described in Southeast Asia that were linked to artemisinin resistance were detected in our samples. The use of bitherapies in the treatment of malaria can delay the apparition of drug resistance. Also, the very short half-life of artemisinin is not favorable for the selection of resistant parasite. These two factors could explain the fact that, less than 10 years after ACT implementation, no molecular markers for artemisinin resistance was observed. Those results were consistent with previous studies in Africa.[@b10-idr-11-1329],[@b12-idr-11-1329]--[@b17-idr-11-1329],[@b64-idr-11-1329] The A578S mutation was detected in one isolate (0.4%). This mutation was often reported in Africa but it had a low prevalence (\<2%).[@b10-idr-11-1329],[@b12-idr-11-1329],[@b17-idr-11-1329]--[@b20-idr-11-1329],[@b22-idr-11-1329],[@b23-idr-11-1329] This mutation was also identified in Bangladesh.[@b65-idr-11-1329] However, A578S mutation was not associated with artemisinin treatment failure and all the patients carrying the mutant parasites were cured by artemether--lumefantrine or ASAQ before day 3.[@b10-idr-11-1329],[@b21-idr-11-1329] Furthermore, the absence of a role for the A578S mutation in artemisinin resistance was confirmed in an in vitro study using site-directed mutagenesis.[@b10-idr-11-1329] Two others mutations, V494A (0.4%) and A504V (0.9%), were identified for the first time in two isolates. A non-synonymous mutation V494I was observed in Angola and in Mozambique but was not associated with artemisinin resistance.[@b66-idr-11-1329] This study described new *PfK13* polymorphisms, but the lack of an in vitro assay did not allow us to determine the absence of resistance to artemisinin in the southeast of Gabon. However, the role of *PfK13* polymorphisms in artemisinin derivatives in Africa is still debated. Recent publications reported that parasites collected from African patients who were still parasitemic at day 3 and beyond did not carry mutations in *PfK13* after ACT treatment.[@b67-idr-11-1329]--[@b70-idr-11-1329]

Conclusion
==========

This study showed a high prevalence of a *Pfcrt*-resistant haplotype in Gabon between 2011 and 2014 (\>70%), even though chloroquine was no longer used. Despite a great diversity and variable distribution of the alleles linked to SP susceptibility, no resistant quintuple mutation haplotypes associated with IPTp-SP failure have been found in this period. Since ACT implementation, there is not yet artemisinin resistance in Southeast Gabon. However, the spread of antimalarial drug resistance from Southeast Asia to Africa, as described for chloroquine and SP, requires an intensive epidemiological survey.[@b71-idr-11-1329],[@b72-idr-11-1329]
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###### 

Primer sequences and hybridization temperatures

  Genes                                       Codons mutations          Primers                                                       Temperature (°C)
  ------------------------------------------- ------------------------- ------------------------------------------------------------- ------------------
  *Pfcrt*                                     72, 73, 74, 75, 76        5′-CCG TTA ATA ATA ATA CAC GCA G-3′                           55
  5′-CGG ATG TTA CAA AAC TAT AGT TAC C-3′                                                                                             
  *Pfdhfr*                                    51, 59, 108, 164          5′-CAT TTT GCT GCC GGT CAC TCC TTT TTA TGA TGG AAC AAG T-3′   52
  5′-AAA ATA AAC AAA ATC ATC TTC TTC TTC-3′                                                                                           
  *Pfdhps*                                    436, 437, 540, 581, 613   5′-TGC TTA AAT GAT ATG ATA CCC GAA TAT AAG-3′                 52
  5′-TCC ACC TGA AAA GAA ATA CAT AAA T-3′                                                                                             
  *PfK13*                                                               5′-GGGAATCTGGTGGTAACAGC-3′                                    58
  Primary PCR                                                           5′-CGGAGTGACCAAATCTGGGA-3′                                    
  *PfK13*                                                               5′-GCCTTGTTGAAAGAAGCAGA-3′                                    60
  Nested PCR                                                            5′-GCCAAGCTGCCATTCATTTG-3′                                    

**Abbreviation:** PCR, polymerase chain reaction.

###### 

Characteristics of study samples

  Study sites             Character                 2011                      2012                         2013                         2014   *p*-value
  ----------------------- ------------------------- ------------------------- ---------------------------- ---------------------------- ------ -----------
  Franceville             No of subjects            29                        30                           27                           28     
  Sex ratio (M/F)         1.9                       1.14                      0.92                         0.59                                
  Mean age                53.39 (6--154)            58.20 (13--166)           78.96 (41--168)              66.20 (24--156)              0.49   
  Geometric parasitemia   7,068.68 (350--147,500)   9,982.81 (100--200,000)   17,022.40 (1,750--453,600)   8,878.64 (420--369,600)      0.29   
  Koulamoutou             No of subjects                                                                   29                           30     
  Sex ratio (M/F)                                                             0.93                         1.5                                 
  Mean age                                                                    41.87 (8--168)               50.19 (5--156)               0.75   
  Geometric parasitemia                                                       2,905.12 (72--31, 320)       2,192.31 (72--37, 440)       0.59   
  Lastourville            No of subjects                                                                   30                           30     
  Sex ratio (M/F)                                                             1.73                         1.14                                
  Mean age                                                                    36.07 (12--108)              36.23 (10--156)              0.36   
  Geometric parasitemia                                                       17,754.41 (105--425,600)     16,586.84 (1,260--285,600)   0.5    

**Notes:** Geometric means of age (months) with interquartile ranges; geometric means of parasitemia (parasites/mL) with interquartile ranges.

**Abbreviations:** F, female; M, male.

###### 

Prevalence of Pfcrt haplotypes

  Study sites    Year          CVMNK (%)   CVIET (%)   Multiple clones (%)   *p*-value
  -------------- ------------- ----------- ----------- --------------------- -----------
  Franceville    2011 (n=17)   5.9         88.2        5.9                   0.06
  2012 (n=25)    3.7           96.3        0.0                               
  2013 (n=19)    10.5          78.9        10.5                              
  2014 (n=17)    29.4          70.6        0.0                               
  Koulamoutou    2013 (n=25)   12.0        84.0        4.0                   0.22
  2014 (n=28)    3.7           96.3        0.0                               
  Lastourville   2013 (n=28)   7.1         89.3        3.6                   1
  2014 (n=17)    5.9           94.1        0.0                               
  All sites      2013 (N=72)   9.7         84.7        5.9                   0.15
  2014 (N=62)    11.5          88.5        0.0                               

###### 

Prevalence of *Pfdhfr* and *Pfdhps* haplotypes

  Study sites    Years   *Pfdhfr*   *Pfdhps*   *Pfdhfr*+*Pfdhps*                                                                                 
  -------------- ------- ---------- ---------- ------------------- ----- ----- ------ ------ ------ ------ ------- ------ ------ ------- ------- ------
  Franceville    2011    15         0.0        100.0               0.0   0.0   0.6    4      0.0    0.0    100.0   0.0    0.48   3       100.0   0.32
  2012           23      0.0        95.7       4.3                 0.0         0      0.0    0.0    0.0    0.0            0      0.0             
  2013           22      0.0        100.0      0.0                 0.0         12     0.0    8.3    83.3   8.3            12     100.0           
  2014           19      5.3        89.4       0.0                 0.0         10     10.0   30.0   50.0   10.0           9      88.9            
  Koulamoutou    2013    23         0.0        100.0               0.0   0.0   1      19     15.8   0.0    68.4    15.8   0.33   15      73.3    0.32
  2014           26      0.0        100.0      0.0                 0.0         22     8.3    8.3    83.3   0.0            12     91.7            
  Lastourville   2013    29         0.0        96.6                0.0   3.4   1      22     4.6    0.0    86.4    9.1    0.24   24      83.3    0.32
  2014           17      0.0        94.1       0.0                 5.9         7      14.3   14.3   71.4   0.0            7      100.0           
  All sites      2013    74         0.0        98.6                0.0   1.4   0.54   53     6.9    1.7    72.4    19     0.05   51      80.4    1
  2014           62      1.6        95.2       0.0                 1.6         29     9.7    16.1   64.5   9.7            28     92.9            

**Note:** Quadruple mutations = *Pfdhfr* (51+59+108) and *Pfdhps* (437).
